StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio r&d expenses

Research and development expenses are spending on new products and technology.

Regenxbio's R&D Expenses for the twelve months ending Jun 30, 2026 was $229.14M, up 5.4% year over year. For fiscal 2025 it was $228.30M, up 9.5% from the year before. Over ten years it grew 29.4% a year on average. The highest annual figure on record is $242.45M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$228.30M+9.5%
FY2024Dec 31, 2024$208.52M-10.2%
FY2023Dec 31, 2023$232.27M-4.2%
FY2022Dec 31, 2022$242.45M+33.6%
FY2021Dec 31, 2021$181.44M+9.1%
FY2020Dec 31, 2020$166.29M+33.9%
FY2019Dec 31, 2019$124.19M+48.1%
FY2018Dec 31, 2018$83.87M+46.6%
FY2017Dec 31, 2017$57.22M+25.8%
FY2016Dec 31, 2016$45.48M+163.2%
FY2015Dec 31, 2015$17.28M+248.3%
FY2014Dec 31, 2014$4.96M-1.8%
FY2013Dec 31, 2013$5.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$56.09M-5.7%
Q1 FY2026Mar 31, 2026$57.34M+8.0%
Q4 FY2025Dec 31, 2025$59.61M+18.3%
Q3 FY2025Sep 30, 2025$56.10M+3.1%
Q2 FY2025Jun 30, 2025$59.50M+21.8%
Q1 FY2025Mar 31, 2025$53.09M-3.2%
Q4 FY2024Dec 31, 2024$50.38M-9.5%
Q3 FY2024Sep 30, 2024$54.43M-6.5%
Q2 FY2024Jun 30, 2024$48.87M-18.4%
Q1 FY2024Mar 31, 2024$54.84M-6.3%
Q4 FY2023Dec 31, 2023$55.68M-10.9%
Q3 FY2023Sep 30, 2023$58.18M-8.1%
Q2 FY2023Jun 30, 2023$59.89M-1.8%
Q1 FY2023Mar 31, 2023$58.52M+5.2%
Q4 FY2022Dec 31, 2022$62.51M+30.3%
Q3 FY2022Sep 30, 2022$63.31M+32.3%
Q2 FY2022Jun 30, 2022$61.01M+33.0%
Q1 FY2022Mar 31, 2022$55.63M+40.0%
Q4 FY2021Dec 31, 2021$47.98M+1.7%
Q3 FY2021Sep 30, 2021$47.86M+8.8%
Q2 FY2021Jun 30, 2021$45.88M+20.4%
Q1 FY2021Mar 31, 2021$39.72M+7.3%
Q4 FY2020Dec 31, 2020$47.18M+39.6%
Q3 FY2020Sep 30, 2020$43.97M+23.2%
Q2 FY2020Jun 30, 2020$38.11M+29.3%
Q1 FY2020Mar 31, 2020$37.04M+46.9%
Q4 FY2019Dec 31, 2019$33.81M+39.0%
Q3 FY2019Sep 30, 2019$35.69M+92.8%
Q2 FY2019Jun 30, 2019$29.48M+37.2%
Q1 FY2019Mar 31, 2019$25.20M+28.9%
Q4 FY2018Dec 31, 2018$24.33M+71.7%
Q3 FY2018Sep 30, 2018$18.51M+47.9%
Q2 FY2018Jun 30, 2018$21.49M+54.4%
Q1 FY2018Mar 31, 2018$19.55M+17.6%
Q4 FY2017Dec 31, 2017$14.17M-11.8%
Q3 FY2017Sep 30, 2017$12.52M-0.3%
Q2 FY2017Jun 30, 2017$13.92M–
Q1 FY2017Mar 31, 2017$16.62M–
Q4 FY2016Dec 31, 2016$16.06M–
Q3 FY2016Sep 30, 2016$12.56M–

More Regenxbio figures

See a number that looks wrong?